Oxford Biomedica PLC Axovant update on 2nd cohort of SUNRISE-PD trial (2646B)
October 06 2020 - 6:46AM
UK Regulatory
TIDMOXB
RNS Number : 2646B
Oxford Biomedica PLC
06 October 2020
Oxford Biomedica notes Axovant's positive six-month follow-up
from second cohort of SUNRISE-PD Phase 2 trial of AXO-Lenti-PD
Oxford, UK - 6 October, 2020: Oxford Biomedica plc (LSE:OXB)
("Oxford Biomedica" or "the Group"), a leading gene and cell
therapy group, notes Axovant Gene Therapies' ("Axovant") positive
six-month follow-up data from the second cohort of the SUNRISE-PD
Phase 2 trial of AXO-Lenti-PD gene therapy in Parkinson's
disease.
Key highlights from the follow-up data were as follows:
-- AXO-Lenti-PD was well-tolerated with no treatment-related
serious adverse events at 6 months
-- 21-point mean improvement in UPDRS Part III "OFF" score, a
40% improvement from baseline based on the two evaluable patients
in the study, exceeding predefined criteria for success
-- Greater than 2-hour improvement from baseline in both diary
"good ON time" and diary OFF time assessments
-- EXPLORE-PD, a randomised, sham-controlled study of
AXO-Lenti-PD is expected to begin dosing in 2021
To view the full announcement from Axovant, please follow this
link: (LINK)
In June 2018, Oxford Biomedica out-licenced OXB-102 (later
renamed AXO-Lenti-PD) to Axovant through a $842.5 million worldwide
licence agreement (LINK). In July 2020 a three year clinical supply
agreement was additionally signed with Axovant to manufacture GMP
batches to support the ongoing and future clinical development of
AXO-Lenti-PD (LINK).
-Ends-
Enquiries:
Oxford Biomedica plc T: +44 (0)1865 783 000
John Dawson, Chief Executive Officer T: +44 (0)1865 783 000
Stuart Paynter, Chief Financial Officer T: +44 (0)1865 954 161 / E: ir@oxb.com
Catherine Isted, Head of Corporate
Development & IR
T: +44 (0)20 3709 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene
and cell therapy group focused on developing life changing
treatments for serious diseases. Oxford Biomedica and its
subsidiaries (the "Group") have built a sector leading lentiviral
vector delivery platform (LentiVector(R)), which the Group
leverages to develop in vivo and ex vivo products both in-house and
with partners. The Group has created a valuable proprietary
portfolio of gene and cell therapy product candidates in the areas
of oncology, ophthalmology, CNS disorders, liver diseases and
respiratory disease. The Group has also entered into a number of
partnerships, including with Novartis, Bristol Myers Squibb,
Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Beam
Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene
Therapy Consortium and Imperial Innovations, through which it has
long-term economic interests in other potential gene and cell
therapy products. Additionally the group has signed a 3 year master
supply and development agreement with AstraZeneca for large-scale
manufacturing of the adenoviral based COVID-19 vaccine candidate,
AZD1222. Oxford Biomedica is based across several locations in
Oxfordshire, UK and employs more than 580 people. Further
information is available at www.oxb.com
About Axovant Gene Therapies
Axovant Gene Therapies is a clinical-stage gene therapy company
focused on developing a pipeline of innovative product candidates
for debilitating neurodegenerative diseases. Our current pipeline
of gene therapy candidates targets GM1 gangliosidosis, GM2
gangliosidosis (also known as Tay-Sachs disease and Sandhoff
disease), and Parkinson's disease. Axovant is focused on
accelerating product candidates into and through clinical trials
with a team of experts in gene therapy development and through
external partnerships with leading gene therapy organizations. For
more information, visit www.axovant.com
About AXO-Lenti-PD
AXO-Lenti-PD is an investigational gene therapy for the
treatment of Parkinson's disease that is designed to deliver three
genes (tyrosine hydroxylase, cyclohydrolase 1, and aromatic L-amino
acid decarboxylase) via a single lentiviral vector to encode a set
of critical enzymes required for dopamine synthesis, with the goal
of reducing variability and restoring steady levels of dopamine in
the brain. The investigational gene therapy aims to provide patient
benefit for years following a single administration. Axovant
expects to dose the first patient in EXPLORE-PD, a randomized, sham
controlled study in 2021.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUPGRWUUPUGGQ
(END) Dow Jones Newswires
October 06, 2020 07:46 ET (11:46 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024